ProPhase Labs Inc Asset Resilience Ratio

Latest as of June 2025: 0.00%

ProPhase Labs Inc asset resilience ratio. ProPhase Labs Inc (PRPH) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ProPhase Labs Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$2.00K

Cash + Short-term Investments

Total Assets

$42.04 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of ProPhase Labs Inc (2011–2024)

Asset resilience ratio of ProPhase Labs Inc from 2011 to 2024. This chart shows how ProPhase Labs Inc's Asset Resilience Ratio has changed over time. Read ProPhase Labs Inc (PRPH) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down ProPhase Labs Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PRPH total assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$2.00K	0.0%
Total Liquid Assets	$2.00K	0.00%

Asset Resilience Insights

Limited Liquidity: ProPhase Labs Inc maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

ProPhase Labs Inc Industry Peers by Asset Resilience Ratio

Compare ProPhase Labs Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Revvity Inc. NYSE:RVTY	Diagnostics & Research	0.00%
Hangzhou Tigermed Consulting SHE:300347	Diagnostics & Research	0.11%
Cowealth Medical China Co.Ltd. SHG:603122	Diagnostics & Research	2.25%
SMO ClinPlus Co. Ltd. SHE:301257	Diagnostics & Research	15.78%
Eurofins-Cerep SA PA:ALECR	Diagnostics & Research	13.42%
Sonic Healthcare Ltd AU:SHL	Diagnostics & Research	0.13%
Integral Diagnostics Ltd AU:IDX	Diagnostics & Research	0.03%
Australian Clinical Labs Ltd AU:ACL	Diagnostics & Research	4.11%

ProPhase Labs Inc Asset Resilience Ratio by Year (2011–2024)

ProPhase Labs Inc asset resilience ratio by year from 2011 to 2024. The table below shows the annual Asset Resilience Ratio data for ProPhase Labs Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.00%	$0.00	$63.20 Million	--
2023-12-31	3.40%	$3.13 Million	$91.93 Million	-6.10pp
2022-12-31	9.50%	$8.33 Million	$87.65 Million	-0.41pp
2021-12-31	9.92%	$8.86 Million	$89.30 Million	+4.70pp
2020-12-31	5.22%	$1.64 Million	$31.41 Million	-2.33pp
2019-12-31	7.54%	$926.00K	$12.27 Million	-24.70pp
2018-12-31	32.25%	$6.69 Million	$20.74 Million	-22.68pp
2017-12-31	54.93%	$18.77 Million	$34.16 Million	--
2016-12-31	0.00%	$0.00	$12.80 Million	--
2015-12-31	0.00%	$0.00	$14.83 Million	--
2014-12-31	0.00%	$0.00	$16.06 Million	--
2013-12-31	0.00%	$0.00	$17.42 Million	--
2012-12-31	0.00%	$0.00	$16.66 Million	--
2011-12-31	0.00%	$0.00	$19.08 Million	--

pp = percentage points

About ProPhase Labs Inc

NASDAQ:PRPH USA Diagnostics & Research

Market Cap

$238.57K

Market Cap Rank

#31311 Global

#6353 in USA

Share Price

$0.02

Change (1 day)

-9.47%

52-Week Range

$0.02 - $0.97

All Time High

$14.70